Carnitine deficiency can occur when the body is unable to absorb or obtain enough carnitine from food, leading to symptoms such as weakness in muscles, fatigue, irritability, and delayed movement development
Tirzepatide is administered as a once-weekly subcutaneous injection, with dosing typically initiated at 2.5 mg and gradually titrated upward based on glycemic control and tolerability
Periods of illness, high stress, poor sleep, or significant dietary changes can temporarily alter immune function, making injection site reactions more or less pronounced
Meet with our physicians to discuss FDA-approved options like semaglutide or tirzepatide that are available now
This dual benefit makes it an attractive option for individuals with both obesity and cardiovascular risk factors
2- What is the difference between Semaglutide and Tirzepatide